Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Insider Neil Gallagher Sells 4,618 Shares

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) insider Neil Gallagher sold 4,618 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the transaction, the insider now directly owns 85,095 shares of the company’s stock, valued at $1,318,972.50. The trade was a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ SNDX opened at $14.86 on Thursday. Syndax Pharmaceuticals, Inc. has a 1 year low of $12.06 and a 1 year high of $25.34. The firm’s 50 day moving average price is $14.00 and its 200 day moving average price is $17.27.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Values First Advisors Inc. acquired a new position in Syndax Pharmaceuticals in the third quarter valued at $30,000. R Squared Ltd purchased a new stake in Syndax Pharmaceuticals in the 4th quarter valued at about $26,000. Quantbot Technologies LP acquired a new position in shares of Syndax Pharmaceuticals during the 3rd quarter valued at about $49,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Syndax Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after acquiring an additional 541 shares during the last quarter. Finally, Cape Investment Advisory Inc. lifted its holdings in shares of Syndax Pharmaceuticals by 157.1% during the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock worth $85,000 after acquiring an additional 3,927 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on SNDX shares. JPMorgan Chase & Co. upped their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, November 21st. HC Wainwright restated a “buy” rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, December 10th. StockNews.com downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. The Goldman Sachs Group increased their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Scotiabank cut their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $36.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).